| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CDK14 |
| Uniprot No | O94921 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-469aa |
| 氨基酸序列 | MCDLIEPQPA EKIGKMKKLR RTLSESFSRI ALKKDDTTFD EICVTKMSTR NCQGMDSVIK PLDTIPEDKK VRVQRTQSTF DPFEKPANQV KRVHSENNAC INFKTSSTGK ESPKVRRHSS PSSPTSPKFG KADSYEKLEK LGEGSYATVY KGKSKVNGKL VALKVIRLQE EEGTPFTAIR EASLLKGLKH ANIVLLHDII HTKETLTLVF EYVHTDLCQY MDKHPGGLHP DNVKLFLFQL LRGLSYIHQR YILHRDLKPQ NLLISDTGEL KLADFGLARA KSVPSHTYSN EVVTLWYRPP DVLLGSTEYS TCLDMWGVGC IFVEMIQGVA AFPGMKDIQD QLERIFLVLG TPNEDTWPGV HSLPHFKPER FTLYSSKNLR QAWNKLSYVN HAEDLASKLL QCSPKNRLSA QAALSHEYFS DLPPRLWELT DMSSIFTVPN VRLQPEAGES MRAFGKNNSY GKSLSNSKH |
| 预测分子量 | 53 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CDK14重组蛋白的参考文献示例，包含文献名称、作者及摘要内容概括：
---
1. **文献名称**：*"Recombinant CDK14 Kinase Activity and Interaction with Wnt Signaling Components"*
**作者**：Smith J. et al.
**摘要**：本研究在大肠杆菌系统中成功表达并纯化了重组CDK14蛋白，验证其体外激酶活性，并发现其与Wnt通路中的β-catenin存在磷酸化相互作用，提示CDK14可能通过调控Wnt信号影响细胞周期进程。
2. **文献名称**：*"CDK14-Cyclin Y Complex Formation and Its Role in Cancer Cell Invasion"*
**作者**：Zhang L. et al.
**摘要**：通过共表达CDK14和Cyclin Y的重组蛋白，揭示了二者形成功能性复合物的结构基础，并证明该复合物通过磷酸化DVL2蛋白增强结直肠癌细胞的迁移和侵袭能力。
3. **文献名称**：*"Structural Insights into CDK14 Activation by Cyclin Y Using Recombinant Proteins"*
**作者**：Johnson R. et al.
**摘要**：利用昆虫细胞系统表达CDK14和Cyclin Y重组蛋白，通过冷冻电镜解析复合物结构，发现Cyclin Y结合诱导CDK14激酶结构域构象变化，为靶向抑制剂设计提供依据。
4. **文献名称**：*"Recombinant CDK14 as a Potential Biomarker in Pancreatic Cancer Progression"*
**作者**：Wang Q. et al.
**摘要**：在哺乳动物细胞中制备高纯度CDK14重组蛋白，开发特异性抗体并用于临床样本分析，发现CDK14在胰腺癌组织中异常高表达，且与患者预后不良显著相关。
---
**备注**：以上文献为示例，实际研究中请通过PubMed、Web of Science等数据库检索最新发表的论文获取准确信息。
**Background of CDK14 Recombinant Protein**
Cyclin-dependent kinase 14 (CDK14), also known as PFTAIRE1 or PFTK1. is a member of the CDK family of serine/threonine kinases. CDK14 plays a critical role in regulating cell cycle progression and signal transduction pathways. Unlike canonical CDKs (e.g., CDK1/2/4/6), CDK14 lacks direct cyclin-binding motifs but interacts with specific cyclin partners, such as Cyclin Y or Cyclin O, to modulate its kinase activity. This interaction is essential for its involvement in the Wnt/β-catenin signaling pathway, where CDK14 phosphorylates key components to promote transcriptional activation of target genes linked to cell proliferation and differentiation.
Structurally, CDK14 contains a conserved kinase domain and a unique PEST-rich C-terminal region, which may regulate protein stability and interactions. Dysregulation of CDK14 has been implicated in various cancers, including colorectal, hepatocellular, and breast cancers, where its overexpression correlates with tumor growth, metastasis, and poor prognosis. Additionally, CDK14 is associated with neurological disorders, highlighting its diverse physiological roles.
Recombinant CDK14 proteins are engineered using expression systems (e.g., *E. coli* or mammalian cells) to ensure proper folding and post-translational modifications. These proteins are vital tools for studying CDK14’s biochemical properties, substrate specificity, and inhibitor screening. Researchers utilize purified CDK14 recombinant proteins in kinase assays, structural studies (e.g., X-ray crystallography), and cell-based experiments to explore its regulatory mechanisms and therapeutic potential.
Understanding CDK14’s molecular functions through recombinant proteins contributes to drug discovery, particularly in targeting CDK14-driven pathways in cancer and other diseases. However, challenges remain in elucidating its context-dependent roles and developing selective inhibitors due to structural similarities among CDK family members. Ongoing research aims to unravel CDK14’s complex biology and translate findings into clinical applications.
×
